Conference Track

HIV Management in Resource-Constrained Settings

Source: CCO Official Conference Coverage of the 2009 IAS Conference on HIV Pathogenesis, Treatment and Prevention

Capsule Summaries

Cluster Randomized Trial Demonstrates That Lay Workers Can Effectively Provide Home-Based HIV Care to Patients in Poor Communities
Nurse-Led, Community-Supported HIV/AIDS Care in Lesotho Produces Clinical Outcomes Comparable With Other Cohorts in Sub-Saharan Africa
High Rates of Treatment Success in an Integrated Adult and Pediatric Antiretroviral Treatment Center in Cape Town, South Africa
Screening for Cryptococcal Antigen in Ugandan Patients Initiating Antiretroviral Therapy at Low CD4+ Counts Reduces Early Mortality
Incidence of Septicemia Remains High in HIV-Infected Individuals in Rural Ugandan Cohort During First Year of Antiretroviral Therapy but Declines Thereafter
Concurrent Antiretroviral Therapy and Cotrimoxazole Prophylaxis Significantly Reduced the Risk of Malaria Among HIV-Infected Ugandan Patients
DART: Access to CD4+ Cell Count Monitoring Associated With Small But Significant Reductions in New AIDS Diagnosis or Death Among Ugandan Patients Initiating Antiretroviral Therapy
Decline in Tuberculosis Prevalence Temporally Associated With Rollout of Antiretroviral Therapy Program in South African Community

Expert Analysis

HIV Management in Resource-Constrained Settings: the DART Trial

Faculty:

James Hakim, MBChB, MMed, MSc, FRCP
Elly Katabira, MD
Mauro Schechter, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss disease progression rates with laboratory monitoring vs clinical monitoring in the DART trial
Describe the effect of cotrimoxazole on mortality in patients initiating antiretroviral therapy in the DART trial
Explain the results pertaining to clinical progression in patients initiating therapy with triple-NRTI vs NNRTI-based regimens in the DART trial
Relate rates of adverse events with laboratory monitoring vs clinical monitoring in the DART trial
Cite data on the renal toxicity and the use of tenofovir in patients participating in the DART trial

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: October 12, 2009

Expiration Date: October 11, 2010

Physicians: maximum of 0.5 AMA PRA Category 1 Credits™

Registered Nurses: 0.5 Nursing contact hours

Pharmacists: 0.5 contact hours (0.05 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.